异源初免-加强型新冠疫苗接种对埃塞俄比亚来说是一个担忧还是一个机遇？ - Suppr

Suppr

超能文献

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?

作者信息

Gelanew Tesfaye, Wassie Liya, Mulu Andargachew, Wondwossen Liya, Abebe Markos, Mihret Adane, Abdissa Alemseged

机构信息

Armauer Hansen Research Institute, Addis Ababa, Ethiopia.

Federal Ministry of Health, Addis Ababa, Ethiopia.

出版信息

Front Public Health. 2023 Jan 26;10:1046546. doi: 10.3389/fpubh.2022.1046546. eCollection 2022.

DOI:10.3389/fpubh.2022.1046546

PMID:36777764

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9909475/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a8be/9909475/e782a9422505/fpubh-10-1046546-g0001.jpg

相似文献

Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?

Front Public Health. 2023 Jan 26;10:1046546. doi: 10.3389/fpubh.2022.1046546. eCollection 2022.

Homologous versus Heterologous prime-boost COVID-19 Vaccination in autologous hematopoietic stem cell transplantation recipients: a blinded randomized controlled trial.

Front Immunol. 2023 Aug 1;14:1237916. doi: 10.3389/fimmu.2023.1237916. eCollection 2023.

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.

Hum Vaccin Immunother. 2023 Dec 31;19(1):2206360. doi: 10.1080/21645515.2023.2206360. Epub 2023 May 4.

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines.

Hum Vaccin Immunother. 2022 Nov 30;18(5):2052525. doi: 10.1080/21645515.2022.2052525. Epub 2022 Mar 24.

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.

Infect Dis Poverty. 2022 May 13;11(1):53. doi: 10.1186/s40249-022-00977-x.

Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.

EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.

J Formos Med Assoc. 2022 Apr;121(4):766-777. doi: 10.1016/j.jfma.2022.02.020. Epub 2022 Mar 16.

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study.

Lancet Reg Health Eur. 2021 Dec;11:100249. doi: 10.1016/j.lanepe.2021.100249. Epub 2021 Oct 18.

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.

Lancet Respir Med. 2021 Nov;9(11):1255-1265. doi: 10.1016/S2213-2600(21)00357-X. Epub 2021 Aug 13.

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine.

Biomed Pharmacother. 2022 Mar;147:112650. doi: 10.1016/j.biopha.2022.112650. Epub 2022 Jan 19.

引用本文的文献

Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.

Clin Infect Dis. 2025 Jul 22;80(Supplement_1):S37-S46. doi: 10.1093/cid/ciaf130.

本文引用的文献

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination.

Front Immunol. 2022 Oct 4;13:1010835. doi: 10.3389/fimmu.2022.1010835. eCollection 2022.

Evaluation of the Safety and Immunogenicity of Fractional Intradermal COVID-19 Vaccines as a Booster: A Pilot Study.

Vaccines (Basel). 2022 Sep 8;10(9):1497. doi: 10.3390/vaccines10091497.

A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.

Inquiry. 2022 Jan-Dec;59:469580221124821. doi: 10.1177/00469580221124821.

Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens.

Nat Commun. 2022 Aug 11;13(1):4710. doi: 10.1038/s41467-022-32321-0.

Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.

Cell Rep Med. 2022 Aug 16;3(8):100706. doi: 10.1016/j.xcrm.2022.100706. Epub 2022 Aug 3.

COVID-19 vaccine acceptability and determinants among pregnant mothers attending antenatal care services at Debre Markos town public health institutions, Debre Markos Northwest Ethiopia: mixed study.

Pan Afr Med J. 2022 Apr 12;41:293. doi: 10.11604/pamj.2022.41.293.32618. eCollection 2022.

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants.

J Biomed Sci. 2022 Jul 7;29(1):49. doi: 10.1186/s12929-022-00830-1.

COVID-19 vaccine hesitancy in Addis Ababa, Ethiopia: a mixed-method study.

BMJ Open. 2022 May 30;12(5):e052432. doi: 10.1136/bmjopen-2021-052432.

Pan-coronavirus vaccine pipeline takes form.

Nat Rev Drug Discov. 2022 May;21(5):324-326. doi: 10.1038/d41573-022-00074-6.

COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness.

Lancet Glob Health. 2022 Apr;10(4):e570-e573. doi: 10.1016/S2214-109X(22)00075-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验